• Recordati signed a license deal with Ionis for exclusive rights to develop and commercialize zilganersen outside the U.S. for Alexander disease.
• Recordati will handle regulatory filings and commercialization ex-U.S., including country-level early-access support; Ionis keeps U.S. commercialization.
• Ionis will receive an upfront payment of USD 30 million.
• Ionis is eligible for additional milestone payments and tiered royalties up to the mid-20% range on annual net sales.
• Zilganersen showed positive pivotal-study data, meeting the primary endpoint with 50 mg stabilizing gait speed versus control at Week 61.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recordati Industria Chimica e Farmaceutica S.p.A. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.